Galunisertib Drives Treg Fragility and Promotes Dendritic Cell-Mediated Immunity against Experimental Lymphoma

Galunisertib (LY2157299) is a selective ATP-mimetic inhibitor of TGF-β receptor-I activation, currently under clinical trial in a variety of cancers. We have tested the combined effects of galunisertib- and interleukin-15-activated dendritic cells in an aggressive and highly metastatic murine lympho...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:iScience
Asıl Yazarlar: Hira, Sumit Kumar, Rej, Abhinandan, Paladhi, Ankush, Singh, Ranjeet, Saha, Jayasree, Mondal, Indrani, Bhattacharyya, Sankar, Manna, Partha Pratim
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7559877/
https://ncbi.nlm.nih.gov/pubmed/33089111
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.isci.2020.101623
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller